Mazyar Shadman, MD, MPH, is the Innovators Network Endowed Chair and an associate professor, in theClinical Research Division at Fred Hutchinson Cancer. He is also an associate professor in the Medical Oncology Division at University of Washington School of Medicine.
Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, presents updated SEQUOIA Arm D results demonstrating deep, durable responses and favorable safety with fixed-duration zanubrutinib plus venetoclax in treatment-naive CLL/SLL, including patients with del(17p)/TP53 mutations.
Read More
Dr. Mazyar Shadman presents a network meta-analysis evaluating Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL, showing that zanubrutinib demonstrated the greatest efficacy in reducing progression and death compared to other BTK inhibitors and treatments.
Read More
Dr. Mazyar Shadman presents an OncLive Rapid Readout on the SEQUOIA study, highlighting 5-year follow-up data that confirm zanubrutinib’s sustained progression-free survival superiority over bendamustine plus rituximab in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma, with consistent efficacy across risk groups and a favorable long-term safety profile.
Read More
Dr Shadman on Zanubrutinib in CLL/SLL Intolerant to Prior BTK Inhibitors
October 8th 2023Mazyar Shadman, MD, MPH, discusses preliminary long-term findings from the evaluation of zanubrutinib in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were intolerant to ibrutinib and/or acalabrutinib.
Read More
Dr. Shadman on the Efficacy and Safety of Zanubrutinib in CLL
September 7th 2023Mazyar Shadman, MD, MPH, discusses the efficacy and safety of zanubrutinib in chronic lymphocytic leukemia, as well as data derived from the agents use which supports the regulatory approval of zanubrutinib in this patient population.
Read More
Dr. Shadman on the Exploration of the CAR T-Cell Therapy MB-106 in NHL/CLL
August 8th 2022Mazyar Shadman, MD, MPH, discusses the exploration of MB-106, a third-generation CD20-targeted autologous CAR T-cell therapy, in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Read More
Dr. Shadman on Methods Utilized to Evaluate MB-106 in B-NHL and CLL
January 12th 2022Mazyar Shadman, MD, MPH, discusses the methods utilized in an ongoing phase 1/2 trial evaluating MB-106, an investigational CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Read More
Dr. Shadman on the Safety Profile of a CD20-Directed CAR T-Cell Therapy in B-NHL and CLL
December 22nd 2021Mazyar Shadman, MD, MPH, discusses the safety profile of MB-106, a third-generation, CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Read More